Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGEN), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nervgen Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nervgen Pharma's position in the market.
NervGen Pharma (NASDAQ:NGEN) announced its common shares began trading on Nasdaq on January 8, 2026. The company is a clinical-stage biopharmaceutical developer of neuroreparative therapeutics, advancing NVG-291 for spinal cord injury (SCI).
Recent expanded Phase 1b/2a CONNECT SCI data (announced Nov 24, 2025) showed statistically significant improvements in upper-limb corticospinal signaling and reductions in hyperactive reticulospinal signaling, with reported durable functional and quality-of-life gains in chronic SCI. NervGen plans an FDA End-of-Phase 2 meeting in early 2026 to align on development and registration pathways.
FAQ
What is the current stock price of Nervgen Pharma (NGEN)?
What is the market cap of Nervgen Pharma (NGEN)?
